missing translation for 'onlineSavingsMsg'
Learn More
Learn More
CD11b Rat anti-Mouse, PE, Clone: M1/70, BD
Rat Monoclonal Antibody
Marca: BD Biosciences 561689
74.50 EUR hasta el 2025-12-31
Use el código promocional "25339" para aplicar la oferta.
Este artículo no se puede devolver.
Vea la política de devoluciones
Descripción
The M1/70 antibody reacts with the 170kDa α[M] chain of Mac-1 (CD11b/CD18, α[M]β2 integrin), also known as complement receptor 3 (CR3), which mediates adhesion to C3bi and ICAM-1 (CD54). Mac-1 is expressed at varying levels on granulocytes, macrophages, myeloid-derived dendritic cells, natural killer cells, microglia, and B-1 cells. Mac-1 expression is rapidly up-regulated on neutrophils after activation, in the same time period that CD62L (L-selectin) is shed from the cell surface. M1/70 antibody reportedly blocks cell adherence and C3bi binding, but it does not block cell-mediated lysis. Cross-reaction of mAb M1/70 with CD11b on human monocytes, polymorphonuclear leukocytes, and NK cells has been reported. This antibody is routinely tested by flow cytometric analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.
Host Species: Rat
Clone: M1/70
Isotype: IgG2b, κ
Cross Reactivity: Mouse
Flow Cytometry
Especificaciones
| CD11b | |
| Monoclonal | |
| 0.2mg/mL | |
| Itgam; Integrin alpha-M; Ly-40; Mac-1a; Mac-1 alpha; CR3A; CR-3 alpha chain | |
| Rat | |
| Affinity Purified | |
| RUO | |
| Human, Mouse | |
| IgG2b κ |
| Flow Cytometry | |
| M1/70 | |
| PE | |
| Aqueous buffered solution containing ≤0.09% sodium azide. | |
| Mouse Splenic Cells | |
| 25 μg | |
| Primary | |
| Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. |
Corrección del contenido de un producto
Proporcione sus comentarios sobre el contenido del producto rellenando el siguiente formulario.
Título del producto
CD11b Rat anti-Mouse, PE, Clone: M1/70, BD > 25μg; PE
For Research Use Only.
¿Detecta una oportunidad de mejora?Comparta una corrección de contenido
